The Valley Desk

NCT02605174 · Interventional trial

Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

Overall registry status Completed

Phase 3

Conditions Migraine With or Without Aura

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov